CLINICAL STUDY: ELECTROPHYSIOLOGY
Antiarrhythmic drug therapy in the Multicenter UnSustained Tachycardia Trial (MUSTT): drug testing and as-treated analysis
D. George Wyse, MD, PhD, FACC*,
Mario Talajic, MD, FACC ,
Gail E. Hafley, MS ,
Alfred E. Buxton, MD, FACC ,
L. Brent Mitchell, MD||,
Teresa K. Kus, MD, PhD, FACC||,
Douglas L. Packer, MD, FACC¶,
William H. Kou, MD, FACC#,
Robert Lemery, MD, FACC**,
Peter Santucci, MD,
Denise Grimes, RN,
Kathleen Hickey, RN,
Carolyn Stevens, RN¶,
Steven N. Singh, MD, FACC|| for the MUSTT Investigators
* University of Calgary, Calgary, Alberta, Canada
Montreal Heart Institute, Montreal, Quebec, Canada
Duke Clinical Research Institute, Durham, North Carolina, USA
Temple University Hospital School of Medicine, Philadelphia, Pennsylvania, USA
|| Sacre Coeur Hospital, Montreal, Quebec, Canada
¶ Mayo Clinic Foundation, Rochester, Minnesota, USA
# Veteran’s Administration Medical Center, Ann Arbor, Michigan, USA
** Rhode Island Hospital, Providence, Rhode Island, USA
Rush-Presbyterian Hospital, Chicago, Illinois, USA
Thoracic and Cardiovascular Institute, Lansing, Michigan, USA
Columbia University Medical Center, New York, New York, USA
|| Veteran’s Administration Medical Center, Washington, District of Columbia, USA
Manuscript received November 10, 2000;
revised manuscript received March 22, 2001,
accepted April 26, 2001.
Reprint requests and correspondence: Dr. D. George Wyse, Division of Cardiology, University of Calgary, G009, Health Sciences Center, 3350 Hospital Drive Northwest, Calgary, AB Canada T2N 4N1
dgwyse{at}ucalgary.ca
OBJECTIVES
Using data from the Multicenter UnSustained Tachycardia Trial (MUSTT), we examined the factors used to select antiarrhythmic drug therapy and their impact on outcomes.
BACKGROUND
The MUSTT examined the use of programmed ventricular stimulation (PVS) to guide antiarrhythmic therapy in patients with coronary arteriosclerosis, left ventricular dysfunction and asymptomatic, unsustained ventricular tachycardia (VT). Trial outcomes may reflect factors used to select antiarrhythmic drug therapy.
METHODS
We compared subgroups of patients with inducible sustained VT randomized to PVS-guided antiarrhythmic therapy (n = 351), in particular those receiving PVS-guided antiarrhythmic drug therapy (n = 142) versus no antiarrhythmic therapy (controls, n = 353).
RESULTS
"Effective" antiarrhythmic drug therapy (i.e., the term "effective" was used to denote therapy that resulted in noninducible VT or hemodynamically stable induced VT) was found for 142 of the 351 patients (43%), most often at the first or second PVS session (125/142, 88%). Mortality among the 142 patients did not differ from that among control patients. Of these 142 patients, the PVS end point was noninducibility in 91 patients and stable VT in 51 patients. Mortality did not differ between these two groups either, but arrhythmia was numerically more frequent in the PVS-induced stable VT group. Mortality was greatest in the few patients receiving propafenone (unadjusted p = 0.07, adjusted p = 0.14 vs. controls), but mortality with all agents did not differ from that of controls, even after adjustment.
CONCLUSIONS
Even when presenting the results as favorably as possible, we found no benefit with PVS-guided drug therapy in patients with clinical unsustained VT who had inducible sustained VT. These findings are unaltered by using different end points for PVS or considering the response to individual drugs.
|
Abbreviations and Acronyms
| | ICD | = implantable cardioverter defibrillator | | MUSTT | = Multicenter UnSustained Tachycardia Trial | | PVS | = programmed ventricular stimulation | | VT | = ventricular tachycardia |
|
This article has been cited by other articles:
|
|
|
|
 
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)
J. Am. Coll. Cardiol.,
September 5, 2006;
48(5):
e247 - e346.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace,
September 1, 2006;
8(9):
746 - 837.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G Katritsis and A.J. Camm
Nonsustained ventricular tachycardia: where do we stand?
Eur. Heart J.,
July 1, 2004;
25(13):
1093 - 1099.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kirchhof, H. Degen, M. R. Franz, L. Eckardt, L. Fabritz, P. Milberg, S. Laer, J. Neumann, G. Breithardt, and W. Haverkamp
Amiodarone-Induced Postrepolarization Refractoriness Suppresses Induction of Ventricular Fibrillation
J. Pharmacol. Exp. Ther.,
April 1, 2003;
305(1):
257 - 263.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. Soejima and W. G. Stevenson
Ventricular Tachycardia Associated With Myocardial Infarct Scar: A Spectrum of Therapies for a Single Patient
Circulation,
July 9, 2002;
106(2):
176 - 179.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Does Electrophysiology Testing Adequately Guide Management of Unsustained VT?
Journal Watch Cardiology,
October 12, 2001;
2001(1012):
6 - 6.
[Full Text]
|
|
|
|
|
|
|
J. W. Mason
Mindfully mining MUSTT
J. Am. Coll. Cardiol.,
August 1, 2001;
38(2):
352 - 354.
[Full Text]
[PDF]
|
|
|
|
